Zacks Investment Research upgraded shares of Fibrocell Science Inc (NASDAQ:FCSC) from a hold rating to a buy rating in a research note issued to investors on Wednesday. The firm currently has $4.25 price objective on the stock.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Several other equities research analysts have also weighed in on the company. ValuEngine lowered Fibrocell Science from a sell rating to a strong sell rating in a research report on Friday, June 2nd. HC Wainwright restated a buy rating and issued a $5.70 price target on shares of Fibrocell Science in a research note on Friday, June 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Fibrocell Science presently has an average rating of Buy and a consensus price target of $3.36.
Shares of Fibrocell Science (FCSC) opened at 3.83 on Wednesday. The company has a 50-day moving average price of $2.75 and a 200 day moving average price of $1.65. Fibrocell Science has a one year low of $1.57 and a one year high of $4.64. The company’s market capitalization is $56.28 million.
Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.29. Fibrocell Science had a negative return on equity of 236.55% and a negative net margin of 4,307.60%. Equities analysts anticipate that Fibrocell Science will post ($1.39) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Fibrocell Science Inc (FCSC) Stock Rating Upgraded by Zacks Investment Research” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/07/18/fibrocell-science-inc-fcsc-stock-rating-upgraded-by-zacks-investment-research.html.
A hedge fund recently raised its stake in Fibrocell Science stock. Renaissance Technologies LLC raised its position in Fibrocell Science Inc (NASDAQ:FCSC) by 272.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 194,000 shares of the company’s stock after buying an additional 141,900 shares during the period. Renaissance Technologies LLC owned approximately 0.44% of Fibrocell Science worth $122,000 as of its most recent SEC filing. Institutional investors and hedge funds own 54.97% of the company’s stock.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Fibrocell Science Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fibrocell Science Inc and related companies.